首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Cholesterol Import by Aspergillus fumigatus and Its Influence on Antifungal Potency of Sterol Biosynthesis Inhibitors
【2h】

Cholesterol Import by Aspergillus fumigatus and Its Influence on Antifungal Potency of Sterol Biosynthesis Inhibitors

机译:烟曲霉导入胆固醇及其对甾醇生物合成抑制剂抗真菌效力的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

High mortality rates from invasive aspergillosis in immunocompromised patients are prompting research toward improved antifungal therapy and better understanding of fungal physiology. Herein we show that Aspergillus fumigatus, the major pathogen in aspergillosis, imports exogenous cholesterol under aerobic conditions and thus compromises the antifungal potency of sterol biosynthesis inhibitors. Adding serum to RPMI medium led to enhanced growth of A. fumigatus and extensive import of cholesterol, most of which was stored as ester. Growth enhancement and sterol import also occurred when the medium was supplemented with purified cholesterol instead of serum. Cells cultured in RPMI medium with the sterol biosynthesis inhibitors itraconazole or voriconazole showed retarded growth, a dose-dependent decrease in ergosterol levels, and accumulation of aberrant sterol intermediates. Adding serum or cholesterol to the medium partially rescued the cells from the drug-induced growth inhibition. We conclude that cholesterol import attenuates the potency of sterol biosynthesis inhibitors, perhaps in part by providing a substitute for membrane ergosterol. Our findings establish significant differences in sterol homeostasis between filamentous fungi and yeast. These differences indicate the potential value of screening aspergillosis antifungal agents in serum or other cholesterol-containing medium. Our results also suggest an explanation for the antagonism between itraconazole and amphotericin B, the potential use of Aspergillus as a model for sterol trafficking, and new insights for antifungal drug development.
机译:免疫受损患者的侵袭性曲霉病死亡率高,正促使人们朝着改进抗真菌治疗和更好地了解真菌生理学的方向进行研究。本文中我们显示,烟曲霉是曲霉病的主要病原体,在有氧条件下会导入外源胆固醇,从而损害了固醇生物合成抑制剂的抗真菌效力。将血清添加到RPMI培养基中可导致烟曲霉生长增强,并大量进口胆固醇,其中大部分以酯形式存储。当培养基中添加纯化的胆固醇而不是血清时,也会促进生长和固醇导入。用固醇生物合成抑制剂伊曲康唑或伏立康唑在RPMI培养基中培养的细胞显示出生长迟缓,麦角固醇水平的剂量依赖性下降以及异常甾醇中间体的积累。向培养基中添加血清或胆固醇可以部分地使细胞摆脱药物诱导的生长抑制。我们得出的结论是,胆固醇的导入会减弱甾醇生物合成抑制剂的效力,这可能部分是通过提供膜麦角固醇的替代品来实现的。我们的发现建立了丝状真菌和酵母菌之间固醇稳态的显着差异。这些差异表明在血清或其他含胆固醇的培养基中筛选曲霉菌抗真菌剂的潜在价值。我们的研究结果也为伊曲康唑和两性霉素B之间的拮抗作用,曲霉菌作为固醇贩运模型的潜在用途以及抗真菌药物开发的新见解提供了解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号